Re-mark
Zanidatamab-hrii (Ziihera) is a bispecific HER2-targeted antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). By binding to two distinct HER2 epitopes, Zanidatamab enhances HER2-targeted activity and offers a precision treatment option for eligible patients with advanced disease. It is supplied as a 300 mg lyophilized powder for injection in a single-dose vial, with dosing and administration performed according to the approved prescribing information and individual patient requirements.
You may like
Skin Tightening Injection Delhi for Smooth Skin
I am Dr Ganesh Nagarajan, a GI and Liver cancer surgeon based in Mumbai, with over 22+ years of experience in…
Best Cancer Surgery Clinic in Mumbai , Mumbai Cancer Specialist, Best Cancer Treatment Mumbai , Cancer Surgery Clinic, Cancer Second Opinion Online
A urinary tract infection (UTI) is an infection in any part of the urinary system, which includes the kidneys, ureters,…
Urinary Tract Infection Treatment, Urinary tract infection